2021
The potential impact of triage protocols on racial disparities in clinical outcomes among COVID-positive patients in a large academic healthcare system
Roy S, Showstark M, Tolchin B, Kashyap N, Bonito J, Salazar MC, Herbst JL, Nash KA, Tiako M, Jubanyik K, Kim N, Galusha D, Wang KH, Oladele C. The potential impact of triage protocols on racial disparities in clinical outcomes among COVID-positive patients in a large academic healthcare system. PLOS ONE 2021, 16: e0256763. PMID: 34529684, PMCID: PMC8445412, DOI: 10.1371/journal.pone.0256763.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlack or African AmericanConnecticutCOVID-19Delivery of Health CareFemaleHealthcare DisparitiesHispanic or LatinoHospital MortalityHospitals, UniversityHumansMaleMiddle AgedOrgan Dysfunction ScoresPandemicsRetrospective StudiesSARS-CoV-2TriageWhite PeopleYoung AdultConceptsCOVID-positive patientsHigher SOFA scoreSOFA scoreClinical outcomesBlack patientsHospital mortalityICU admissionTriage protocolYale New Haven Health SystemSequential Organ Failure Assessment scoreHealthcare systemLarge academic healthcare systemOrgan Failure Assessment scoreRacial disparitiesSimilar clinical outcomesWorse clinical outcomesAcademic healthcare systemChi-square testRace/ethnicityPredictors of interestRetrospective cohortWhite patientsInsurance statusCOVID patientsTriage tool
2017
Economic evaluation of a behavioral intervention versus brief advice for substance use treatment in pregnant women: results from a randomized controlled trial
Xu X, Yonkers KA, Ruger JP. Economic evaluation of a behavioral intervention versus brief advice for substance use treatment in pregnant women: results from a randomized controlled trial. BMC Pregnancy And Childbirth 2017, 17: 83. PMID: 28270105, PMCID: PMC5341449, DOI: 10.1186/s12884-017-1260-5.Peer-Reviewed Original ResearchConceptsBrief adviceMET-CBTClinical outcomesPregnant womenPsychotropic medicationsHealth care system perspectiveBehavioral interventionsSevere substance use disordersIntervention costsSimilar clinical outcomesOverall medical costsNon-medical costsCost of careCost-minimization analysisSubstance use disordersQuality of lifeWilcoxon rank sum testSubstance use treatmentMotivational enhancement therapyCognitive behavioral therapyRank sum testFetal morbidityPostpartum periodClinical trialsIntake assessment
2013
Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy
Nazif T, Mehran R, Lee E, Fahy M, Parise H, Stone G, Kirtane A. Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. American Heart Journal 2013, 167: 43-50. PMID: 24332141, DOI: 10.1016/j.ahj.2013.10.013.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa receptor inhibitorsNet adverse clinical eventsMajor adverse cardiac eventsHigh-risk acute coronary syndromesAcute coronary syndromeMajor bleedingCoronary syndromeComposite major adverse cardiac eventsIIb/IIIa receptor inhibitorsGlycoprotein IIb/IIIa inhibitorsEarly invasive management strategyIIb/IIIa inhibitorsInvasive management strategySafety of tirofibanAdverse cardiac eventsSimilar clinical outcomesAdverse clinical eventsUse of tirofibanComparative effectiveness analysisSignificant differencesACUITY trialAcute CatheterizationUpstream tirofibanMultivariable adjustmentUpstream therapy
2009
Quality of Life of Early Stage Breast Cancer Patients 65 Years Old or Older Randomized to Standard Chemotherapy or Capecitabine: A Cancer and Leukemia Group B Study (CALGB 49907).
Kornblith A, Archer L, Lan L, Kimmick G, Partridge A, Casey R, Bennett S, Hudis C, Winer E, Cohen H, Muss H. Quality of Life of Early Stage Breast Cancer Patients 65 Years Old or Older Randomized to Standard Chemotherapy or Capecitabine: A Cancer and Leukemia Group B Study (CALGB 49907). Cancer Research 2009, 69: 5035-5035. DOI: 10.1158/0008-5472.sabcs-09-5035.Peer-Reviewed Original ResearchEnd of treatmentSimilar clinical outcomesStandard chemotherapyClinical outcomesCapecitabine patientsQoL resultsTreatment recommendationsLess toxicityLeukemia Group B StudyRandomized phase III trialBetter overall QoLPatients 65 yearsStandard chemotherapy armOlder cancer patientsPhase III trialsWorse clinical outcomesSystemic side effectsBetter body imageQuality of lifeCapecitabine armChemotherapy armLess constipationWorse diarrheaCapecitabine treatmentMetastatic setting
2008
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial
Lansky AJ, Tsuchiya Y, Brener M, Mehran R, Cristea E, Pietras C, Grines CL, Cox DA, Garcia E, Tcheng JE, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Leon MB, Moses J, Stone GW. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheterization And Cardiovascular Interventions 2008, 72: 917-924. PMID: 19016469, DOI: 10.1002/ccd.21714.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinClopidogrelCoronary AngiographyDrug Therapy, CombinationEuropeFemaleHemorrhageHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionMyocardial IschemiaPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentStentsThrombosisTiclopidineTime FactorsTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionPrimary stentingCADILLAC trialRecurrent ischemiaSevere bleedingMyocardial infarctionEfficacy of clopidogrelMore recurrent ischemiaTIMI 0/1 flowSimilar clinical outcomesTiclopidine treatmentAngiographic characteristicsClopidogrel useIndependent predictorsClinical outcomesMultivariable analysisRandomized trialsStent thrombosisStent implantationOperator's discretionClopidogrelStentingPatientsTiclopidineRelative safetyRacial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both
Prisant LM, Thomas KL, Lewis EF, Huang Z, Francis GS, Weaver WD, Pfeffer MA, McMurray JJ, Califf RM, Velazquez EJ. Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both. Journal Of The American College Of Cardiology 2008, 51: 1865-1871. PMID: 18466801, DOI: 10.1016/j.jacc.2007.12.050.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsBiomarkersBlack or African AmericanCaptoprilFemaleHeart FailureHospitalizationHumansIncidenceMaleMiddle AgedMyocardial InfarctionRetrospective StudiesRisk FactorsSystoleTetrazolesUnited StatesValineValsartanVentricular Dysfunction, LeftWhite PeopleConceptsLeft ventricular systolic dysfunctionHeart failureAcute myocardial infarctionMyocardial infarctionBaseline characteristicsAfrican AmericansMyocardial Infarction ComplicatedAngiotensin receptor blockersCoronary risk factorsOutcomes of patientsRecurrent myocardial infarctionVentricular systolic dysfunctionSimilar clinical outcomesHF hospitalizationCardiovascular morbidityCause mortalityReceptor blockersSystolic dysfunctionVentricular dysfunctionCardiovascular mortalityWhite patientsClinical outcomesPoor outcomeVALIANT trialSubgroup analysis
2007
Evaluating the role of HLA‐DQ polymorphisms on immune response to bacterial superantigens using transgenic mice
Rajagopalan G, Polich G, Sen M, Singh M, Epstein B, Lytle A, Rouse M, Patel R, David C. Evaluating the role of HLA‐DQ polymorphisms on immune response to bacterial superantigens using transgenic mice. HLA 2007, 71: 135-145. PMID: 18086265, DOI: 10.1111/j.1399-0039.2007.00986.x.Peer-Reviewed Original ResearchConceptsStreptococcal mitogenic exotoxin ZClass II moleculesHLA class II moleculesHLA-DQ6HLA-DQ8Transgenic miceBacterial superantigensImmune responseHLA class II transgenic miceHLA-DQ8 transgenic miceHuman leukocyte antigen (HLA) class II moleculesHLA class II allelesToxic shock syndrome toxin-1II transgenic miceSimilar clinical outcomesHLA-DQ polymorphismStreptococcal pyrogenic exotoxin AHLA class IIVivo immune responseHLA class II polymorphismClass II allelesPyrogenic exotoxin ASyndrome toxin-1Superantigen-mediated diseasesClass II polymorphism
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply